Bristol Myers Squibb (CELG-RI) Change in Inventory (2009 - 2026)

Bristol Myers Squibb has disclosed Change in Inventory across 18 years of filings, most recently posting -$14.0 million for Q1 2026.

• In Q1 2026, Change in Inventory fell 108.28% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 99.77% YoY), while the FY2025 annual figure was $184.0 million, down 62.14% from the prior year.
• Change in Inventory advanced to -$14.0 million in Q1 2026, from -$71.0 million in the prior quarter.
• Over the last five years, Change in Inventory for CELG-RI reached as high as $282.0 million in Q1 2023 and fell as low as -$175.0 million in Q4 2024.
• The 5-year median for Change in Inventory is $41.0 million (2022), against an average of $86.8 million.
• Annual changes were most pronounced in 2023 — Change in Inventory jumped 28300.0% — and 2024, when it tumbled 188.83%.
• A 5-year view of Change in Inventory shows it stood at $41.0 million in 2022, then surged by 380.49% to $197.0 million in 2023, then slumped by 188.83% to -$175.0 million in 2024, then jumped by 59.43% to -$71.0 million in 2025, then surged by 80.28% to -$14.0 million in 2026.
• According to Business Quant data, Change in Inventory over the past three periods registered -$14.0 million, -$71.0 million, and $90.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.